Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Predictive Factors for the First Line Use and the Dose Effectiveness Relationship

NCT03059134 is registered in ClinicalTrials.gov with Buddhist Tzu Chi General Hospital as lead sponsor.

NCT NCT03059134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Predictive Factors for the First Line Use and the Dose Effectiveness Relationship
Lead sponsor
Buddhist Tzu Chi General Hospital
Phase
Phase 3
Overall status
Completed
Start date
April 28, 2015
Completion date
April 27, 2016
Enrollment
168 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome, urinary incontinence